Piqray (alpelisib)

Numéro de dossier de l’APP: 21749
État des négociations:
Under consideration for negotiation
Indication(s):
In combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen
Promoteur/fabricant:
Novartis Pharmaceuticals Canada Inc.
Numéro de projet de l’ACMTS:
PC0247
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation:
Not Applicable